Klassen Preston 4
4 · Regulus Therapeutics Inc. · Filed Jan 15, 2025
Insider Transaction Report
Form 4
Klassen Preston
DirectorPresident & Head of R & D
Transactions
- Sale
Common Stock
2025-01-13$1.26/sh−31,445$39,721→ 36,055 total
Footnotes (1)
- [F1]The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) which commenced vesting on January 9, 2025. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.